These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21965474)

  • 21. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
    Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
    BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
    Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
    J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced risk of prostate cancer in U.S. Men with AIDS.
    Shiels MS; Goedert JJ; Moore RD; Platz EA; Engels EA
    Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2910-5. PubMed ID: 20837717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
    Brenner H; Arndt V
    J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer incidence and mortality trends among elderly and adult Europeans.
    Vercelli M; Quaglia A; Marani E; Parodi S
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):133-44. PubMed ID: 10936470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
    Coory MD; Baade PD
    Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
    Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
    Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality.
    Etzioni R; Legler JM; Feuer EJ; Merrill RM; Cronin KA; Hankey BF
    J Natl Cancer Inst; 1999 Jun; 91(12):1033-9. PubMed ID: 10379966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rise and fall of radical prostatectomy rates from 1989 to 1996.
    Sheikh K; Bullock C
    Urology; 2002 Mar; 59(3):378-82. PubMed ID: 11880074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer in Saskatchewan Canada, before and during the PSA era.
    Skarsgard D; Tonita J
    Cancer Causes Control; 2000 Jan; 11(1):79-88. PubMed ID: 10680732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
    Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
    J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of screening on incidence and mortality of prostate cancer in the United States.
    Potosky AL; Feuer EJ; Levin DL
    Epidemiol Rev; 2001; 23(1):181-6. PubMed ID: 11588846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expected population impacts of discontinued prostate-specific antigen screening.
    Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
    Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.
    Quinn M; Babb P
    BJU Int; 2002 Jul; 90(2):162-73. PubMed ID: 12081758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
    Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
    J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.